Neuraxpharm expands Southern European presence with move into Portugal
Germany-headquartered central nervous system (CNS) specialist Neuraxpharm Group today announced the expansion of its operations in Southern Europe with the launch of Neuraxpharm Portugal. Based in Lisbon, Neuraxpharm Portugal will be part of the company’s Southern European Region that comprises Italy, Spain and now Portugal.
Neuraxpharm aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market for the first time. Neuraxpharm will leverage its industry networks and CNS expertise to make its extensive portfolio available to patients. The company is planning the first commercial launch in December this year with a probiotic product.
Javier Mercadé, general manager of Italy and Spain, was appointed head of Southern Region earlier this year, which will include Spain, Italy and Portugal. Neuraxpharm also announced the appointment of Teng Dias as commercial director of the Portugal business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze